$550.3 M

MIRM Mkt cap, 14-Jan-2022
Mirum Pharmaceuticals Net income (FY, 2020)-103.3 M
Mirum Pharmaceuticals EBIT (FY, 2020)-104.3 M
Mirum Pharmaceuticals Cash, 31-Dec-2020142.1 M
Mirum Pharmaceuticals EV411.4 M
Get notified regarding key financial metrics and revenue changes at Mirum PharmaceuticalsLearn more
Banner background

Mirum Pharmaceuticals Income Statement

Annual

USDFY, 2018FY, 2019FY, 2020

R&D expense

2.3m43.0m81.6m

General and administrative expense

585.0k11.8m22.7m

Operating expense total

17.4m54.7m104.3m

EBIT

(17.4m)(54.7m)(104.3m)

Interest expense

14.0k

Interest income

72.0k2.2m1.6m

Pre tax profit

(52.5m)(103.3m)

Income tax expense

21.0k6.0k

Net Income

(17.3m)(52.6m)(103.3m)

Quarterly

USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

R&D expense

4.9m11.6m12.2m17.3m18.6m

General and administrative expense

1.3m2.4m3.7m4.7m5.0m

Operating expense total

6.2m14.0m15.9m22.0m23.6m

EBIT

(6.2m)(14.0m)(15.9m)(22.0m)(23.6m)

Interest expense

5.0k

Interest income

235.0k468.0k749.0k405.0k

Pre tax profit

(21.3m)(23.2m)

Income tax expense

4.0k3.0k

Net Income

(6.0m)(13.6m)(15.1m)(21.3m)(23.3m)

Mirum Pharmaceuticals Balance Sheet

Annual

USDFY, 2018FY, 2019FY, 2020

Cash

52.0m12.0m142.1m

Prepaid Expenses

12.0k2.7m4.5m

Current Assets

52.0m119.4m236.4m

PP&E

1.4m1.3m

Total Assets

52.0m146.7m240.9m

Accounts Payable

269.0k3.4m3.2m

Short-term debt

397.0k636.0k

Current Liabilities

2.4m13.1m18.5m

Long-term debt

3.3m2.6m

Total Debt

3.6m3.3m

Total Liabilities

2.4m16.4m68.8m

Common Stock

7.0m2.0k3.0k

Preferred Stock

Additional Paid-in Capital

34.0k200.1m345.2m

Retained Earnings

(17.3m)(69.9m)(173.2m)

Total Equity

(17.3m)130.3m172.1m

Financial Leverage

-3 x1.1 x1.4 x

Quarterly

USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

49.5m41.8m30.8m72.0m83.0m

Prepaid Expenses

263.0k666.0k3.1m2.9m2.7m

Current Assets

49.8m84.9m129.3m162.4m152.1m

PP&E

453.0k460.0k631.0k1.4m1.4m

Total Assets

51.5m104.3m158.3m172.8m155.8m

Accounts Payable

2.4m2.3m2.7m3.3m3.0m

Short-term debt

95.0k511.0k530.0k

Current Liabilities

6.5m11.1m10.9m13.5m16.6m

Long-term debt

1.2m1.2m1.1m3.1m2.9m

Total Debt

1.3m1.2m1.1m3.6m3.5m

Total Liabilities

7.7m12.4m12.1m16.7m19.6m

Common Stock

7.0m1.0k2.0k3.0k3.0k

Preferred Stock

Additional Paid-in Capital

252.0k1.9m198.1m247.4m250.3m

Retained Earnings

(23.3m)(36.9m)(51.9m)(91.2m)(114.5m)

Total Equity

(23.1m)(34.9m)146.2m156.1m136.2m

Debt to Equity Ratio

0 x

Debt to Assets Ratio

0 x

Financial Leverage

-2.2 x-3 x1.1 x1.1 x1.1 x

Mirum Pharmaceuticals Cash Flow

Annual

USDFY, 2018FY, 2019FY, 2020

Net Income

(17.3m)(52.6m)(103.3m)

Depreciation and Amortization

139.0k305.0k

Accounts Payable

2.4m

Cash From Operating Activities

(373.0k)(39.4m)(89.1m)

Purchases of PP&E

(281.0k)(225.0k)

Cash From Investing Activities

(7.5m)(127.8m)37.9m

Cash From Financing Activities

59.8m127.2m181.3m

Net Change in Cash

52.0m(40.0m)130.1m

Income Taxes Paid

11.0k

Quarterly

USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(6.0m)(19.5m)(34.6m)(21.3m)(44.6m)

Depreciation and Amortization

43.0k80.0k73.0k143.0k

Accounts Payable

3.7m

Cash From Operating Activities

(2.4m)(10.4m)(25.7m)(18.4m)(35.3m)

Purchases of PP&E

(44.0k)(44.0k)(214.0k)(98.0k)(151.0k)

Cash From Investing Activities

(44.0k)(58.4m)(122.6m)33.8m61.7m

Cash From Financing Activities

58.8m127.2m44.7m44.7m

Net Change in Cash

(2.5m)(10.1m)(21.1m)60.1m71.1m

Mirum Pharmaceuticals Ratios

USDFY, 2018

Financial Leverage

-3 x